Analgesia pp 145-177 | Cite as

Anti-convulsants and Anti-depressants

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 177)

Abstract

Damage to a nerve should only lead to sensory loss. While this is common, the incidence of spontaneous pain, allodynia and hyperalgesia indicate marked changes in the nervous system that are possible compensations for the loss of normal function that arises from the sensory loss. Neuropathic pain arises from changes in the damaged nerve which then alter function in the spinal cord and the brain and lead to plasticity in areas adjacent to those directly influenced by the neuropathy. The peripheral changes drive central compensations so that the mechanisms involved are multiple and located at a number of sites. Nerve damage increases the excitability of both the damaged and undamaged nerve fibres, neuromas and the cell bodies in the dorsal root ganglion. These peripheral changes are substrates for the ongoing pain and the efficacy of excitability blockers such as carbamazepine, lamotrigine and mexiletine, all anti-convulsants. A better understanding of ion channels at the sites of injury has shown important roles of particular sodium, potassium and calcium channels in the genesis of neuropathic pain. Within the spinal cord, increases in the activity of calcium channels and the receptors for glutamate, especially the N-methyl-D-aspartate (NMDA) receptor, trigger wind-up and central hyperexcitability. Increases in transmitter release, neuronal excitability and receptive field size result from the damage to the peripheral nerves. Ketamine and gabapentin/pregabalin, again with anticonvulsant activity, may interact with these mechanisms. Ketamine acts on central spinal mechanisms of excitability whereas gabapentin acts on a subunit of calcium channels that is responsible for the release of pain transmitters into the spinal cord. In addition to these spinal mechanisms of hyperexcitability, spinal cells participate in a spinal-supraspinal loop that involves parts of the brain involved in affective responses to pain but also engages descending excitatory and inhibitory systems that use the monoamines. These pathways become more active after nerve injury and are the site of action of anti-depressants. This chapter reviews the evidence and mechanisms of drugs, both anti-depressants and anticonvulsants, that are believed to be effective in pain control, with a major emphasis on the neuropathic state.

Keywords

Neuropathic pain Anti-depressants Anti-convulsants Ion channels Monoamines 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abdi S, Lee DH, Chung JM (1998) The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 87:1360–1366PubMedGoogle Scholar
  2. Abe M, Kurihara T, Han W, Shinomiya K, Tanabe T (2002) Changes in expression of voltage-dependent ion channel subunits in dorsal root ganglia of rats with radicular injury and pain. Spine 27:1517–1524; discussion 1525PubMedGoogle Scholar
  3. Ahmad M, Goucke CR (2002) Management strategies for the treatment of neuropathic pain in the elderly. Drugs Aging 19:929–945PubMedGoogle Scholar
  4. Ardid D, Jourdan D, Mestre C, Villanueva L, Le Bars D, Eschalier A (1995) Involvement of bulbospinal pathways in the antinociceptive effect of clomipramine in the rat. Brain Res 695:253–256PubMedGoogle Scholar
  5. Backonja M, Glanzman RL (2003) Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 25:81–104PubMedGoogle Scholar
  6. Backonja MM (2000) Anticonvulsants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 16:S67–S72PubMedGoogle Scholar
  7. Basbaum AI, Fields HL (1978) Endogenous pain control mechanisms: review and hypothesis. Ann Neurol 4:451–462PubMedGoogle Scholar
  8. Bischofs S, Zelenka M, Sommer C (2004) Evaluation of topiramate as an anti-hyperalgesic and neuroprotective agent in the peripheral nervous system. J Peripher Nerv Syst 9:70–78PubMedGoogle Scholar
  9. Bennett MI, Simpson KH (2004) Gabapentin in the treatment of neuropathic pain. Palliat Med 18:5–11PubMedGoogle Scholar
  10. Blackburn-Munro G, Fleetwood-Walker SM (1999) The sodium channel auxiliary subunits beta1 and beta2 are differentially expressed in the spinal cord of neuropathic rats. Neuroscience 90:153–164PubMedGoogle Scholar
  11. Blackburn-Munro G, Dickinson T, Fleetwood-Walker SM (2001) Non-opioid actions of lamotrigine within the rat dorsal horn after inflammation and neuropathic nerve damage. Neurosci Res 39:385–390PubMedGoogle Scholar
  12. Bomholt SF, Mikkelsen JD, Blackburn-Munro G (2005) Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 48:252–263PubMedGoogle Scholar
  13. Campbell FG, Graham JG, Zilkha KJ (1966) Clinical trial of carbazepine (tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiatry 29:265–267PubMedGoogle Scholar
  14. Canavero S, Bonicalzi V (1996) Lamotrigine control of central pain. Pain 68:179–181PubMedGoogle Scholar
  15. Caraceni A, Zecca E, Martini C, De Conno F (1999) Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 17:441–445PubMedGoogle Scholar
  16. Carrazana E, Mikoshiba I (2003) Rationale and evidence for the use of oxcarbazepine in neuropathic pain. J Pain Symptom Manage 25:S31–35PubMedGoogle Scholar
  17. Chadda VS, Mathur MS (1978) Double blind study of the effects of diphenylhydantoin sodium on diabetic neuropathy. J Assoc Physicians India 26:403–406PubMedGoogle Scholar
  18. Cheung H, Kamp D, Harris E (1992) An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 13:107–112PubMedGoogle Scholar
  19. Cheunsuang O, Maxwell D, Morris R (2002) Spinal lamina Ineurones that express neurokinin 1 receptors. II. Electrophysiological characteristics, responses to primary afferent stimulation and effects of a selective mu-opioid receptor agonist. Neuroscience 111:423–434PubMedGoogle Scholar
  20. Chong MS, Libretto SE (2003) The rationale and use of topiramate for treating neuropathic pain. Clin J Pain 19:59–68PubMedGoogle Scholar
  21. Christensen D, Gautron M, Guilbaud G, Kayser V (2001) Effect of gabapentin and lamotrigine on mechanical allodynia-like behaviour in a rat model of trigeminal neuropathic pain. Pain 93:147–153PubMedGoogle Scholar
  22. Clifford DB (1985) Treatment of pain with antidepressants. Am Fam Physician 31:181–185PubMedGoogle Scholar
  23. Collins SL, Moore RA, McQuay HJ, Wiffen P (2000) Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage 20:449–458PubMedGoogle Scholar
  24. Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A (1994) Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics. Pain 57:153–160PubMedGoogle Scholar
  25. David G, Selzer ME, Yaari Y (1985) Suppression by phenytoin of convulsant-induced after-discharges at presynaptic nerve terminals. Brain Res 339:57–65PubMedGoogle Scholar
  26. De Felipe MC, De Ceballos ML, Gil C, Fuentes JA (1985) Chronic antidepressant treatment increases enkephalin levels in N. accumbens and striatum of the rat. Eur J Pharmacol 112:119–122PubMedGoogle Scholar
  27. Dickenson AH, Matthews EA, Suzuki R (2002) Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur J Pain 6Suppl A:51–60PubMedGoogle Scholar
  28. Dogrul A, Gardell LR, Ossipov MH, Tulunay FC, Lai J, Porreca F (2003) Reversal of experimental neuropathic pain by T-type calcium channel blockers. Pain 105:159–168PubMedGoogle Scholar
  29. Dooley DJ, Donovan CM, Pugsley TA(2000) Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 295:1086–1093PubMedGoogle Scholar
  30. Duckrow RB, Taub A (1977) The effect of diphenylhydantoin on self-mutilation in rats produced by unilateral multiple dorsal rhizotomy. Exp Neurol 54:33–41PubMedGoogle Scholar
  31. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM (2003) Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 60:1524–1534PubMedGoogle Scholar
  32. Eisenach JC, Gebhart GF (1995) Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats. Anesthesiology 83:1046–1054PubMedGoogle Scholar
  33. Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A (2001) Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 57:505–509PubMedGoogle Scholar
  34. Erichsen HK, Hao JX, Xu XJ, Blackburn-Munro G (2003) Acomparison of the antinociceptive effects of voltage-activated Na+ channel blockers in two rat models of neuropathic pain. Eur J Pharmacol 458:275–282PubMedGoogle Scholar
  35. Esser MJ, Sawynok J (2000) Caffeine blockade of the thermal antihyperalgesic effect of acute amitriptyline in a rat model of neuropathic pain. Eur J Pharmacol 399:131–139PubMedGoogle Scholar
  36. Farago F (1987) Trigeminal neuralgia: its treatment with two new carbamazepine analogues. Eur Neurol 26:73–83PubMedGoogle Scholar
  37. Field MJ, McCleary S, Hughes J, Singh L (1999) Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain 80:391–398PubMedGoogle Scholar
  38. Fields H (2004) State-dependent opioid control of pain. Nat Rev Neurosci 5:565–575PubMedGoogle Scholar
  39. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS (2002) Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain 96:375–383PubMedGoogle Scholar
  40. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS (2000) Evidence-based data from animal and human experimental studies on pain relief with antidepressants: a structured review. Pain Med 1:310–316PubMedGoogle Scholar
  41. Flatters SJ, Bennett GJ (2004) Ethosuximide reverses paclitaxel-and vincristine-induced painful peripheral neuropathy. Pain 109:150–161PubMedGoogle Scholar
  42. Fox A, Gentry C, Patel S, Kesingland A, Bevan S (2003) Comparative activity of the anticonvulsants oxcarbazepine, carbamazepine, lamotrigine and gabapentin in a model of neuropathic pain in the rat and guinea-pig. Pain 105:355–362PubMedGoogle Scholar
  43. Gauriau C, Bernard JF (2004) A comparative reappraisal of projections from the superficial laminae of the dorsal horn in the rat: the forebrain. J Comp Neurol 468:24–56PubMedGoogle Scholar
  44. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN (1996) The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 271:5768–5776PubMedGoogle Scholar
  45. Glauser TA (1999) Topiramate. Epilepsia 40Suppl 5:S71–80PubMedGoogle Scholar
  46. Gordon DB, Love G (2004) Pharmacologic management of neuropathic pain. Pain Manag Nurs 5:19–33PubMedGoogle Scholar
  47. Grant SM, Faulds D (1992) Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders. Drugs 43:873–888PubMedGoogle Scholar
  48. Gray AM, Pache DM, Sewell RD (1999) Do alpha2-adrenoceptors play an integral role in the antinociceptive mechanism of action of antidepressant compounds? Eur J Pharmacol 378:161–168PubMedGoogle Scholar
  49. Hamon M, Gozlan H, Bourgoin S, Benoliel JJ, Mauborgne A, Taquet H, Cesselin F, Mico JA (1987) Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology 26:531–539PubMedGoogle Scholar
  50. Hansson PT, Dickenson AH (2005) Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain 113: 251–254PubMedGoogle Scholar
  51. Hardy JR, Rees EA, Gwilliam B, Ling J, Broadley K, A’Hern R (2001) A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain. J Pain Symptom Manage 21:204–209PubMedGoogle Scholar
  52. Hunt SP (2000) Pain control: breaking the circuit. Trends Pharmacol Sci 21:284–287PubMedGoogle Scholar
  53. Hunter JC, Gogas KR, Hedley LR, Jacobson LO, Kassotakis L, Thompson J, Fontana DJ (1997) The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 324:153–160PubMedGoogle Scholar
  54. Ikeda H, Heinke B, Ruscheweyh R, Sandkuhler J (2003) Synaptic plasticity in spinal lamina I projection neurons that mediate hyperalgesia. Science 299:1237–1240PubMedGoogle Scholar
  55. Inghilleri M, Conte A, Frasca V, Curra A, Gilio F, Manfredi M, Berardelli A (2004) Antiepileptic drugs and cortical excitability: a study with repetitive transcranial stimulation. Exp Brain Res 154:488–493PubMedGoogle Scholar
  56. Jensen TS (2001) Recent advances in pain research: implications for chronic headache. Cephalalgia 21:765–769PubMedGoogle Scholar
  57. Jensen TS (2002) Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 6Suppl A:61–68PubMedGoogle Scholar
  58. Jensen TS, Gottrup H, Sindrup SH, Bach FW (2001a) The clinical picture of neuropathic pain. Eur J Pharmacol 429:1–11PubMedGoogle Scholar
  59. Jensen TS, Gottrup H, Kasch H, Nikolajsen L, Terkelsen AJ, Witting N (2001b) Has basic research contributed to chronic pain treatment? Acta Anaesthesiol Scand 45:1128–1135PubMedGoogle Scholar
  60. Johannessen CU (2000) Mechanisms of action of valproate: a commentatory. Neurochem Int 37:103–110PubMedGoogle Scholar
  61. Johannessen CU, Johannessen SI (2003) Valproate: past, present, and future. CNS Drug Rev 9:199–216PubMedGoogle Scholar
  62. Jun JH, Yaksh TL (1998) The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed after thermal injury in the rat. Anesth Analg 86:348–354PubMedGoogle Scholar
  63. Killian JM, Fromm GH (1968) Carbamazepine in the treatment of neuralgia. Use of side effects. Arch Neurol 19:129–136PubMedGoogle Scholar
  64. Klamt JG (1998) Effects of intrathecally administered lamotrigine, a glutamate release inhibitor, on short-and long-term models of hyperalgesia in rats. Anesthesiology 88:487–494PubMedGoogle Scholar
  65. La Spina I, Porazzi D, Maggiolo F, Bottura P, Suter F (2001) Gabapentin in painful HIV-related neuropathy: a report of 19 patients, preliminary observations. Eur J Neurol 8:71–75PubMedGoogle Scholar
  66. Lee WS, Limmroth V, Ayata C, Cutrer FM, Waeber C, Yu X, Moskowitz MA (1995) Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 116:1661–1667PubMedGoogle Scholar
  67. Leijon G, Boivie J (1989) Central post-stroke pain—a controlled trial of amitriptyline and carbamazepine. Pain 36:27–36PubMedGoogle Scholar
  68. Levendoglu F, Ogun CO, Ozerbil O, Ogun TC, Ugurlu H (2004) Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine 29:743–751PubMedGoogle Scholar
  69. Loscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31–59PubMedGoogle Scholar
  70. Luo ZD, Chaplan SR, Higuera ES, Sorkin LS, Stauderman KA, Williams ME, Yaksh TL (2001) Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats. J Neurosci 21:1868–1875PubMedGoogle Scholar
  71. Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, Myers RR (2002) Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 303:1199–1205PubMedGoogle Scholar
  72. Maneuf YP, Gonzalez MI, Sutton KS, Chung FZ, Pinnock RD, Lee K (2003) Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci 60:742–750PubMedGoogle Scholar
  73. Marais E, Klugbauer N, Hofmann F (2001) Calciumchannel alpha(2)delta subunits-structure and Gabapentin binding. Mol Pharmacol 59:1243–1248PubMedGoogle Scholar
  74. Martin ED, Pozo MA (2004) Valproate reduced excitatory postsynaptic currents in hippocampal CA1 pyramidal neurons. Neuropharmacology 46:555–561PubMedGoogle Scholar
  75. Matthews EA, Dickenson AH (2001) Effects of spinally delivered N-and P-type voltage-dependent calcium channel antagonists on dorsal horn neuronal responses in a rat model of neuropathy. Pain 92:235–246PubMedGoogle Scholar
  76. Mattia C, Coluzzi F (2003) Antidepressants in chronic neuropathic pain. Mini Rev Med Chem 3:773–784PubMedGoogle Scholar
  77. Mattia C, Paoletti F, Coluzzi F, Boanelli A (2002) New antidepressants in the treatment of neuropathic pain. A review. Minerva Anestesiol 68:105–114Google Scholar
  78. Max MB (1994) Treatment of post-herpetic neuralgia: antidepressants. Ann Neurol 35Suppl:S50–53PubMedGoogle Scholar
  79. Maxwell DJ, Kerr R, Rashid S, Anderson E (2003) Characterisation of axon terminals in the rat dorsal horn that are immunoreactive for serotonin 5-HT3A receptor subunits. Exp Brain Res 149:114–124PubMedGoogle Scholar
  80. McCleane G (1999) 200 mg daily of lamotrigine has no analgesic effect in neuropathic pain: a randomised, double-blind, placebo-controlled trial. Pain 83:105–107PubMedGoogle Scholar
  81. McCleane G (2000) Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol 49:574–579PubMedGoogle Scholar
  82. McCleane GJ, Suzuki R, Dickenson AH (2003) Does a single intravenous injection of the 5HT3 receptor antagonist ondansetron have an analgesic effect in neuropathic pain? A double-blinded, placebo-controlled cross-over study. Anesth Analg 97:1474–1478PubMedGoogle Scholar
  83. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A (1995) Anticonvulsant drugs for management of pain: a systematic review. BMJ 311:1047–1052PubMedGoogle Scholar
  84. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA (1996) A systematic review of antidepressants in neuropathic pain. Pain 68:217–227PubMedGoogle Scholar
  85. Mico JA, Gibert-Rahola J, Casas J, Rojas O, Serrano MI, Serrano JS (1997) Implication of beta 1-and beta 2-adrenergic receptors in the antinociceptive effect of tricyclic antidepressants. Eur Neuropsychopharmacol 7:139–145PubMedGoogle Scholar
  86. Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355–474PubMedGoogle Scholar
  87. Miquel MC, Emerit MB, Nosjean A, Simon A, Rumajogee P, Brisorgueil MJ, Doucet E, Hamon M, Verge D (2002) Differential subcellular localization of the 5-HT3-As receptor subunit in the rat central nervous system. Eur J Neurosci 15:449–457PubMedGoogle Scholar
  88. Monconduit L, Desbois C, Villanueva L (2002) The integrative role of the rat medullary subnucleus reticularis dorsalis in nociception. Eur J Neurosci 16:937–944PubMedGoogle Scholar
  89. Nichols ML, Allen BJ, Rogers SD, Ghilardi JR, Honore P, Luger NM, Finke MP, Li J, Lappi DA, Simone DA, Mantyh PW (1999) Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science 286:1558–1561PubMedGoogle Scholar
  90. Nicol CF (1969) A four year double-blind study of tegretol in facial pain. Headache 9:54–57PubMedGoogle Scholar
  91. Oatway MA, Chen Y, Weaver LC (2004) The 5-HT3 receptor facilitates at-level mechanical allodynia following spinal cord injury. Pain 110:259–268PubMedGoogle Scholar
  92. Okamoto K, Imbe H, Tashiro A, Kimura A, Donishi T, Tamai Y, Senba E (2005) The role of peripheral 5HT2A and 5HT1A receptors on the orofacial formalin test in rats with persistent temporomandibular joint inflammation. Neuroscience 130:465–474PubMedGoogle Scholar
  93. Otto M, Bach FW, Jensen TS, Sindrup SH (2004) Valproic acid has no effect on pain in polyneuropathy: a randomized, controlled trial. Neurology 62:285–288PubMedGoogle Scholar
  94. Peiris JB, Perera GL, Devendra SV, Lionel ND (1980) Sodium valproate in trigeminal neuralgia. Med J Aust 2:278PubMedGoogle Scholar
  95. Perkin GD (1999) Trigeminal neuralgia. Curr Treat Options Neurol 1:458–465PubMedGoogle Scholar
  96. Petersen KL, Maloney A, Hoke F, Dahl JB, Rowbotham MC (2003) A randomized study of the effect of oral lamotrigine and hydromorphone on pain and hyperalgesia following heat/capsaicin sensitization. J Pain 4:400–406PubMedGoogle Scholar
  97. Porreca F, Burgess SE, Gardell LR, Vanderah TW, Malan TP Jr, Ossipov MH, Lappi DA, Lai J (2001) Inhibition of neuropathic pain by selective ablation of brainstem medullary cells expressing the mu-opioid receptor. J Neurosci 21:5281–5288PubMedGoogle Scholar
  98. Porreca F, Ossipov MH, Gebhart GF (2002) Chronic pain and medullary descending facilitation. Trends Neurosci 25:319–325PubMedGoogle Scholar
  99. Ren K, Dubner R (2002) Descending modulation in persistent pain: an update. Pain 100:1–6PubMedGoogle Scholar
  100. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I (1998) Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279:287–291PubMedGoogle Scholar
  101. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L (1998) Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 280:1837–1842PubMedGoogle Scholar
  102. Rush AM, Elliott JR (1997) Phenytoin and carbamazepine: differential inhibition of sodium currents in small cells from adult rat dorsal root ganglia. Neurosci Lett 226:95–98PubMedGoogle Scholar
  103. Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M (2004) Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 109:26–35PubMedGoogle Scholar
  104. Sacerdote P, Brini A, Mantegazza P, Panerai AE (1987) A role for serotonin and betaendorphin in the analgesia induced by some tricyclic antidepressant drugs. Pharmacol Biochem Behav 26:153–158PubMedGoogle Scholar
  105. Saudek CD, Werns S, Reidenberg MM (1977) Phenytoin in the treatment of diabetic symmetrical polyneuropathy. Clin Pharmacol Ther 22:196–199PubMedGoogle Scholar
  106. Schreiber S, Backer MM, Pick CG (1999) The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neurosci Lett 273:85–88PubMedGoogle Scholar
  107. Sierralta F, Pinardi G, Miranda HF (1995) Effect of p-chlorophenylalanine and alphamethyltyrosine on the antinociceptive effect of antidepressant drugs. Pharmacol Toxicol 77:276–280PubMedGoogle Scholar
  108. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K (2000) Aplacebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology 54:2115–2119PubMedGoogle Scholar
  109. Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, Baird BJ, Barrett P, Hammer AE (2003) Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology 60:1508–1514PubMedGoogle Scholar
  110. Sindrup SH, Jensen TS (1999) Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 83:389–400PubMedGoogle Scholar
  111. Sindrup SH, Jensen TS (2000) Pharmacologic treatment of pain in polyneuropathy. Neurology 55:915–920PubMedGoogle Scholar
  112. Sindrup SH, Andersen G, Madsen C, Smith T, Brosen K, Jensen TS (1999) Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 83:85–90PubMedGoogle Scholar
  113. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R (1996) Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29:23–26PubMedGoogle Scholar
  114. Sutton KG, Martin DJ, Pinnock RD, Lee K, Scott RH (2002) Gabapentin inhibits highthreshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br J Pharmacol 135:257–265PubMedGoogle Scholar
  115. Suzuki R, Dickenson AH (2000) Neuropathic pain: nerves bursting with excitement. Neuroreport 11:R17–21PubMedGoogle Scholar
  116. Suzuki R, Morcuende S, Webber M, Hunt SP, Dickenson AH (2002) Superficial NK1-expressing neurons control spinal excitability through activation of descending pathways. Nat Neurosci 5:1319–1326PubMedGoogle Scholar
  117. Suzuki R, Rygh LJ, Dickenson AH (2004a) Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 25:613–617PubMedGoogle Scholar
  118. Suzuki R, Rahman W, Hunt SP, Dickenson AH (2004b) Descending facilitatory control of mechanically evoked responses is enhanced in deep dorsal horn neurones following peripheral nerve injury. Brain Res 1019:68–76PubMedGoogle Scholar
  119. Suzuki R, Rahman W, Rygh LJ, Webber M, Hunt SP, Dickenson AH (2005) Spinal-supraspinal serotonergic circuits regulating neuropathicpain and its treatment with gabapentin. Pain 117:292–303PubMedGoogle Scholar
  120. Tanelian DL, Brose WG (1991) Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine. Anesthesiology 74:949–951PubMedGoogle Scholar
  121. Taylor CP (1997) Mechanisms of action of gabapentin. Rev Neurol (Paris) 153Suppl 1:S39–45PubMedGoogle Scholar
  122. Thienel U, Neto W, Schwabe SK, Vijapurkar U (2004) Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand 110:221–231PubMedGoogle Scholar
  123. Todd AJ (2002) Anatomy of primary afferents and projection neurones in the rat spinal dorsal horn with particular emphasis on substance P and the neurokinin 1 receptor. Exp Physiol 87:245–249PubMedGoogle Scholar
  124. Todd AJ, McGill MM, Shehab SA (2000) Neurokinin 1 receptor expression by neurons in laminae I, III and IV of the rat spinal dorsal horn that project to the brainstem. Eur J Neurosci 12:689–700PubMedGoogle Scholar
  125. Todd AJ, Puskar Z, Spike RC, Hughes C, Watt C, Forrest L (2002) Projection neurons in lamina I of rat spinal cord with the neurokinin 1 receptor are selectively innervated by substance p-containing afferents and respond to noxious stimulation. J Neurosci 22:4103–4113PubMedGoogle Scholar
  126. Tremont-Lukats IW, Megeff C, Backonja MM (2000) Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy. Drugs 60:1029–1052PubMedGoogle Scholar
  127. Urban MO, Gebhart GF (1999) Supraspinal contributions to hyperalgesia. Proc Natl Acad Sci U S A 96:7687–7692PubMedGoogle Scholar
  128. Valverde O, Mico JA, Maldonado R, Mellado M, Gibert-Rahola J (1994) Participation of opioid and monoaminergic mechanisms on the antinociceptive effect induced by tricyclic antidepressants in two behavioural pain tests inmice. Prog Neuropsychopharmacol Biol Psychiatry 18:1073–1092PubMedGoogle Scholar
  129. Wallace MS, Quessy S, Schulteis G (2004) Lack of effect of two oral sodiumchannel antagonists, lamotrigine and 4030W92, on intradermal capsaicin-induced hyperalgesiamodel. Pharmacol Biochem Behav 78:349–355PubMedGoogle Scholar
  130. Waxman SG (1999) The molecular pathophysiology of pain: abnormal expression of sodium channel genesandits contributions to hyperexcitability of primary sensory neurons. Pain Suppl 6:S133–140PubMedGoogle Scholar
  131. Wieczorkiewicz-Plaza A, Plaza P, Maciejewski R, Czuczwar M, Przesmycki K (2004) Effect of to piramate on mechanical allodynia in neuropathic pain model in rats. Pol J Pharmacol 56:275–278PubMedGoogle Scholar
  132. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A (2000) Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev: CD001133Google Scholar
  133. Zakrzewska JM, Patsalos PN (2002) Long-term cohort study comparing medical (oxcarbazepine) and surgical management of intractable trigeminal neuralgia. Pain 95:259–266PubMedGoogle Scholar
  134. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens EL (1997) Lamotrigine (Lamictal) in refractory trigeminal neuralgia: results from a double-blind placebo controlled crossover trial. Pain 73:223–230PubMedGoogle Scholar
  135. Zeitz KP, Guy N, Malmberg AB, Dirajlal S, Martin WJ, Sun L, Bonhaus DW, Stucky CL, Julius D, Basbaum AI (2002) The 5-HT3 subtype of serotonin receptor contributes to nociceptive processing via a novel subset of myelinated and unmyelinated nociceptors. J Neurosci 22:1010–1019PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  1. 1.Dept. PharmacologyUniversity College LondonLondonUK

Personalised recommendations